120241-79-4
120241-79-4 結(jié)構(gòu)式
基本信息
化合物3-TYP
3-(1H-1,2,3-三唑-4-基)吡啶
3-(1H-1,2,3-三唑-5-基)吡啶
CS-2754
Pyridine(3-TYP)
3-TYP
3 TYP
3TYP
3-triazol-4-yl) pyridine
3-(1H-1,2,3-triazol-4-yl)pyridine
Pyridine,3-(1H-1,2,3-triazol-5-yl)-
Pyridine, 3-(1H-1,2,3-triazol-4-yl)- (9CI)
3-(1H-1
2
3-TRIAZOL-4-YL) PYRIDINE
3 TYP
3TYP
物理化學(xué)性質(zhì)
制備方法
2510-23-8
4648-54-8
120241-79-4
一般步驟：向含有3-乙炔基吡啶（0.20 g，1.94 mmol，1.0當(dāng)量）的DMF/MeOH（9:1，4.0 mL）溶液中，依次加入CuI（0.02 g，0.097 mmol，0.05當(dāng)量）和三甲基甲硅烷基疊氮化物（0.38 mL，2.91 mmol，1.5當(dāng)量）。反應(yīng)體系在氮?dú)獗Ｗo(hù)下，于100℃加熱攪拌12小時。反應(yīng)完成后，冷卻至室溫，通過硅藻土墊過濾，并用EtOAc洗滌濾餅。合并濾液，減壓濃縮得到粗產(chǎn)物。粗產(chǎn)物經(jīng)柱色譜純化（洗脫劑：PE/EtOAc = 3:7，隨后為純EtOAc），再用EtOAc結(jié)晶，得到目標(biāo)化合物3-(1H-1,2,3-三唑-4-基)吡啶（0.18 g，收率64%）為白色固體。熔點(diǎn)：187-192℃。1H NMR (300 MHz, CD3OD) δ 9.03 (s, 1H), 8.51 (d, J = 3.7 Hz, 1H), 8.29-8.27 (m, 2H), 7.54-7.50 (m, 1H); 13C NMR (75 MHz, CD3OD) δ 148.3, 146.1, 143.1, 133.9, 127.3, 124.3; MS (ESI) m/z 147 [M + H]+; IR (KBr) 3467, 3118, 1637, 1560, 1434, 1311, 1134 cm-1。元素分析計(jì)算值（C7H6N4）：C, 57.53; H, 4.14; N, 38.34。實(shí)測值：C, 57.67; H, 4.25; N, 38.10。
參考文獻(xiàn)：
[1] European Journal of Medicinal Chemistry, 2012, vol. 55, p. 58 - 66,9
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2026/03/03 | S8628 | 吡啶-3-乙炔 3-TYP | 120241-79-4 | 5mg | 795.01元 |
| 2026/03/03 | S8628 | 吡啶-3-乙炔 3-TYP | 120241-79-4 | 10mM (1mL in DMSO) | 1040.13元 |
| 2026/03/03 | S8628 | 吡啶-3-乙炔 3-TYP | 120241-79-4 | 25mg | 2211.8元 |
常見問題列表
| Target | Value |
|
SIRT3
(cell-free) | 16 nM |
|
SIRT1
(cell-free) | 88 nM |
|
SIRT2
(cell-free) | 92 nM |
在暴露于鎘的HepG2細(xì)胞中，3-TYP可減弱由褪黑色素誘導(dǎo)的去乙?；疭OD2表達(dá)增加及抑制SOD2活性。
3-TYP (50 mg/kg, i.p.) does not significantly influence the LVEF, LVFS, infarct size, serum LDH levels, apoptosis, and oxidative stress compared with those of the Sham group. Moreover, 3-TYP has little effect on gp91phox, Nrf2, NQO 1, Bax, Bcl-2, Caspase-3, and cleaved Caspase-3 expression levels, compared with the Sham group. 3-TYP significantly decreases SIRT3 activity and increases the acetylation of SOD2 compared with that in the control group, without influencing SIRT3 expression. 3-TYP attenuates the cardioprotective effects of melatonin by decreasing the LVEF and LVFS after 24 hour of reperfusion. 3-TYP also increases the infarct size, serum LDH levels, and apoptotic ratio compared with those in the IR+Mel group.